CN110099900A - 针对Smoothened突变株的刺猬通路抑制剂 - Google Patents

针对Smoothened突变株的刺猬通路抑制剂 Download PDF

Info

Publication number
CN110099900A
CN110099900A CN201780080339.9A CN201780080339A CN110099900A CN 110099900 A CN110099900 A CN 110099900A CN 201780080339 A CN201780080339 A CN 201780080339A CN 110099900 A CN110099900 A CN 110099900A
Authority
CN
China
Prior art keywords
compound
alkyl
amino
formula
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780080339.9A
Other languages
English (en)
Other versions
CN110099900B (zh
Inventor
宋淳
张成城
黄牛
张承智
赵昕
张衡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Chengcheng Biotechnology Co ltd
Shandong University
Original Assignee
Jinan Chengcheng Biotechnology Co ltd
Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Chengcheng Biotechnology Co ltd, Shandong University filed Critical Jinan Chengcheng Biotechnology Co ltd
Publication of CN110099900A publication Critical patent/CN110099900A/zh
Application granted granted Critical
Publication of CN110099900B publication Critical patent/CN110099900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

本公开提供了通式I所示的化合物、其药学上可接受的盐、其异构体、溶剂化物、或式I化合物中的任意原子经其同位素替换后得到的化合物，以及该化合物的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201780080339.9A 2016-12-27 2017-12-27 针对Smoothened突变株的刺猬通路抑制剂 Active CN110099900B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016112239084 2016-12-27
CN201611223908 2016-12-27
PCT/CN2017/119014 WO2018121610A1 (zh) 2016-12-27 2017-12-27 针对Smoothened突变株的刺猬通路抑制剂

Publications (2)

Publication Number Publication Date
CN110099900A true CN110099900A (zh) 2019-08-06
CN110099900B CN110099900B (zh) 2022-12-02

Family

ID=62706959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080339.9A Active CN110099900B (zh) 2016-12-27 2017-12-27 针对Smoothened突变株的刺猬通路抑制剂

Country Status (2)

Country Link
CN (1) CN110099900B (zh)
WO (1) WO2018121610A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987067A1 (en) 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
NZ762985A (en) 2017-09-22 2024-03-22 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
HUE061607T2 (hu) 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
CN112300129B (zh) * 2019-07-29 2021-09-14 苏州亚盛药业有限公司 作为bcr-abl抑制剂的杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072755A (zh) * 2004-09-02 2007-11-14 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
BR122021010386B1 (pt) * 2007-06-07 2021-08-03 Sun Pharma Global Fze Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072755A (zh) * 2004-09-02 2007-11-14 遗传技术研究公司 Hedgehog信号转导的吡啶基抑制剂
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLUMBUS，OHIO，US: ""REGISTRY[online]"", 《STN检索报告 US REGISTRY》 *
KIRK D. ROBARGE ET AL.: ""GDC-0449-A potent inhibitor of the hedgehog pathway"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
CN110099900B (zh) 2022-12-02
WO2018121610A1 (zh) 2018-07-05

Similar Documents

Publication Publication Date Title
CN110099900A (zh) 针对Smoothened突变株的刺猬通路抑制剂
EP3578561A1 (en) Spiro compounds
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN107428758A (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN102424681B (zh) 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法
CN101511359A (zh) 苯并***激酶调节剂
BR112018075736B1 (pt) Composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
US9439877B2 (en) Small molecule inhibitors of Dusp6 and uses therefor
CN110981868B (zh) 咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途
CN102803246A (zh) Hedgehog途径拮抗剂及其治疗应用
CN103327972A (zh) 取代的苯甲酰胺及其用途
KR20160093543A (ko) 퀴나졸린 유도체
CN108530337B (zh) 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN114605391B (zh) 喹喔啉类衍生物及其制备方法和应用
CN110114353B (zh) 苯并[b]噻吩酰胺类衍生物及其用途
CN116283953A (zh) 含噻唑结构的吲哚啉类化合物及其制备方法和应用
CN110305125A (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
JP6021148B2 (ja) Ｌｓｔ−１及び／又はｌｓｔ−２によって輸送される化合物
CN106892907B (zh) 含酰腙结构的喹唑啉类化合物及其应用
CN113444074B (zh) 一种具有EGFR和Wnt双重抑制作用的化合物及其制备方法和应用
EP3221307B1 (en) Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
KR101118842B1 (ko) 항암제로 유용한5-(1,3-디아릴-1ｈ-피라졸-4-일메틸렌)-티아졸리딘-2,4-디온 유도체
CN110684022B (zh) Set8赖氨酸甲基转移酶抑制剂及其中间体、制备方法和用途
JP2022513544A (ja) Ｓｅｔ８リジンメチルトランスフェラーゼ阻害剤、その調製方法及び用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant